CSL Seqirus is pleased to provide the following information for the upcoming season:
On February 23rd, 2024, The World Health Organization (WHO) announced the recommendations for the viral composition of influenza vaccines for the 2024-2025 influenza season in the northern hemisphere. For both egg-based quadrivalent and cell or recombinant-based quadrivalent vaccines, the WHO recommends that:
For trivalent vaccines for use in the 2024-2025 northern hemisphere influenza season contain the following:
Egg-based vaccines
- an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
- an A/Thailand/8/2022 (H3N2)-like virus; and
- a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Cell culture- or recombinant-based vaccines
- an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;
- an A/Massachusetts/18/2022 (H3N2)-like virus; and
- a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
For quadrivalent egg- or cell culture-based or recombinant vaccines for use in the 2024-2025 northern hemisphere influenza season, the WHO recommends inclusion of the following as the B/Yamagata lineage component:
- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
If you wish to review the WHO recommendations, please click on the link: 2024-2025 WHO Strain Recommendation
CSL Seqirus is a central partner to clinicians and pharmacists, providing a range of vaccines to offer their patients and consumers innovative options.
CSL Seqirus work with leading Canadian researchers, healthcare professionals and public health leaders to advance scientific knowledge and global influenza research.
National Recommendations
NACI Seasonal Influenza Vaccine Statement
Please click on the links below to access additional customer information.